Pharmacological studies on 1-(7-indenyloxy)-3-isopropylaminopropan-2-Ol hydrochloride (YB-2), a new  -adrenergic blocking agent.
D000315:Adrenalectomy; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000526:Alprenolol / Q000494:pharmacology; D000605:Amino Alcohols / Q000494:pharmacology* / Q000633:toxicity; D000818:Animals; D004837:Epinephrine / Q000037:antagonists & inhibitors; D006168:Guinea Pigs; D006321:Heart / Q000187:drug effects*; D006325:Heart Atria / Q000187:drug effects; D066298:In Vitro Techniques; D007192:Indenes / Q000494:pharmacology*; D007545:Isoproterenol / Q000037:antagonists & inhibitors; D051379:Mice; D009119:Muscle Contraction / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects*; D010042:Ouabain / Q000037:antagonists & inhibitors; D011412:Propanolamines; D011433:Propranolol / Q000494:pharmacology; D011437:Propylamines / Q000494:pharmacology; D051381:Rats; D012110:Reserpine / Q000494:pharmacology; D013237:Stereoisomerism; D014132:Trachea / Q000187:drug effects; D014628:Vagotomy
D000319:Adrenergic beta-Antagonists; D000605:Amino Alcohols; D007192:Indenes; D011412:Propanolamines; D011437:Propylamines; D010042:Ouabain; C002989:indenolol; D000526:Alprenolol; D012110:Reserpine; D011433:Propranolol; D007545:Isoproterenol; D004837:Epinephrine